Engrail Therapeutics

About Engrail Therapeutics

Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019, aiming to become a leader in neuroscience. The company is committed to rapidly advancing innovative, precision-targeted therapeutics to address the needs of patients with devastating and life-limiting disorders.

Products & Services

ENX-102:A therapeutic product in development, specifics not detailed in the content.

Specialties

Precision-targeted therapeutics Molecular mechanisms Complex neurocircuitry Treatment of nervous system disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 157000000 MR: - FA: 157 million FAN: 157000000	D: 2024-03-19 FD: 2024-03-19	10 investors

Series B Latest

2024-03-19

$157.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vikram Sudarsan

President and Chief Executive Officer

K

Kimberly Vanover

Chief Scientific Officer

P

Paul Cayer

Chief Financial Officer

Q

Quentin McCubbin

Chief Technical Officer

E

Eve Taylor

Exec. VP, Clinical Program Management and Regulatory Affairs

B

Bill Brubaker

Sr. VP, Nonclinical Development

View 23 more team members with Pro

Unlock Full Team Directory

Recent News